Health ❯ Healthcare ❯ Clinical Trials

Immunotherapy

Pembrolizumab Autoimmune Diseases Atezolizumab Combination Therapy CAR T-cell Therapy Durvalumab DNA Vaccines Nivolumab mRNA Technology CAR-T-cell Therapy

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Five‑year results show durable drops in metastasis with higher survival, leaving phase 3 confirmation plus manufacturing scale‑up as remaining needs.

Personalized DNA Vaccine Shows Strong Immune Response in Early Glioblastoma Study

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Laser-Guided Tumor Ablation Plus Pembrolizumab More Than Doubles Survival in Recurrent Astrocytoma Trial

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

NICE Backs Obe-cel for Adults With Aggressive Leukaemia as NHS Fast-Tracks Rollout

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Serial Biopsies Reveal Responses Missed by MRI in Glioblastoma CAN-3110 Trial

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

Meta-Analysis Shows 43% Overall Response for Fecal Transplants Combined with Cancer Immunotherapy

Modified Herpes Virus Plus Nivolumab Induces Tumor Regression in Advanced Melanoma

Experimental Vaccine Keeps Kidney Cancer Patients Cancer-Free for Three Years

Immunotherapy Drug Significantly Improves Survival Rates in Bladder Cancer